

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A method for inhibiting replication of Kaposi's sarcoma herpesvirus (KSHV) and receptor tyrosine kinase c-Kit comprising administration of a therapeutically effective amount of a compound that inhibits replication of KSHV and c-Kit signaling pathway.
2. (withdrawn) A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits c-Kit signaling pathway.
3. (withdrawn) A method for inhibiting replication of KSHV comprising administration of a compound that inhibits type I sigma receptor signaling pathway.
4. (withdrawn) A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits type I sigma receptor signaling pathway.
5. (withdrawn) A gene expression profile specific for the lytic phase of KSHV replication comprising at least one gene selected from a group consisting of the genes listed in Table 2.
6. (withdrawn) A gene expression profile specific for the latent phase of KSHV replication comprising at least one gene selected from a group consisting of the genes listed in Table 2.
7. (withdrawn) A microarray comprising nucleic acid encoding a probe to hybridize with one or more of the genes selected from a group consisting of the genes listed in Table 2.

8. (withdrawn) A method for diagnosing KSHV or the stage of KSHV replication comprising:
 - a) obtaining a sample of cells suspected of being infected with KSHV;
 - b) extracting RNA from the cells;
 - c) contacting the RNA with a microarray comprising nucleic acid encoding a probe specific for one or more of the genes selected from a group consisting of the genes listed in Table 2; and
 - d) determining the gene expression profile of the sample of cells and comparing it with the gene expression profile of KSHV infected cells.
9. (withdrawn) A method for identifying modulators of KSHV replication, comprising:
 - a) selecting a gene product from a group of genes consisting of the genes listed in Table 2;
 - b) combining a test compound with the gene product encoded by the gene to determine whether the test compound inhibits or activates the gene product; and
 - c) combining the test compound with KSHV infected cells to determine whether the test compound inhibits or activates replication of the KSHV.
10. (currently amended) A method for inhibiting replication of Kaposi's sarcoma herpesvirus (KSHV) comprising administration of a therapeutically effective amount of a first compound that inhibits receptor tyrosine kinase c-Kit and administration of a therapeutically effective amount of a second compound that modulates KSHV replication by a mechanism other than inhibition of receptor tyrosine kinase c-Kit.
11. (currently amended) The method of claim 10, wherein said second compound that modulates KSHV replication by a mechanism other than inhibition of c-Kit is selected from a group consisting of daunorubicin, doxorubicin, interferon alpha, retinoids, and taxol.

BEST AVAILABLE COPY

12. (withdrawn) A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits c-Kit and administration of a compound that modulates Kaposi sarcoma by a mechanism other than inhibition of c-Kit.
13. (withdrawn) The method of claim 12, wherein said compound that modulates KSHV replication by a mechanism other than inhibition of c-Kit is selected from a group consisting of daunorubicin, doxorubicin, interferon alpha, retinoids, and taxol.
14. (withdrawn) A method for inhibiting replication of KSHV comprising administration of a compound that inhibits type I sigma receptor and administration of a compound that modulates KSHV replication by a mechanism other than inhibition of type I sigma receptor.
15. (withdrawn) The method of claim 14, wherein said compound that modulates KSHV replication by a mechanism other than inhibition of type I sigma receptor is selected from a group consisting of daunorubicin, doxorubicin, interferon alpha, retinoids, and taxol.
16. (withdrawn) A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits type I sigma receptor and administration of a compound that modulates Kaposi sarcoma by a mechanism other than inhibition of type I sigma receptor.
17. (withdrawn) The method of claim 16, wherein said compound that modulates Kaposi sarcoma by a mechanism other than inhibition of type I sigma receptor is selected from a group consisting of daunorubicin, doxorubicin, interferon alpha, retinoids, and taxol.
18. (withdrawn) A method of doing business comprising the steps of:
 - a) determining the level of RNA expression for an RNA sample, wherein said RNA sample;

- b) is amplified and fluorescently labeled, hybridized to a microarray containing a plurality of nucleic acid sequences representing a gene expression profile, and said microarray is scanned for fluorescence;
- c) normalizing said expression level using an algorithm; and
- d) scoring said RNA sample against a gene expression profile database.

19. (withdrawn) The method of claim 18, wherein said RNA sample is obtained from a patient.

20. (withdrawn) The method of claim 19, wherein said RNA sample is isolated from a patient sample selected from the group consisting of blood, amniotic fluid, plasma, semen, bone marrow, and tissue biopsy.

21. (withdrawn) The method of claim 18, wherein said microarray is a DNA microarray.

22. (withdrawn) The method of claim 18, wherein said database is available via a web-browser interface.

23. (withdrawn) The method of claim 18, wherein said web-browser provides gene sequence analysis tools.

24. (withdrawn) The method of claim 18, wherein a user pays a fee for access to said database.